LNP023 (Age-Related Macular Degeneration) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called JNJ-81201887 (the study drug) is a safe and effective option for people with geographic atrophy secondary to age-related macular degeneration.

What is the Condition Being Studied?

Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

Who Can Participate in the Study?

Adults ages 50+ who:

- Are diagnosed with early or intermediate AMD

- Have not had eye surgery, including cataract surgery, within the last 3 months

- Have no active eye inflammation

For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.

Age Group

What is Involved?

If you choose to join the study, you will:

- Get a random assignment (fair, equal chance) to 1 of 3 groups

-- One group will get a higher dose of the study drug

-- A second group will get a lower dose of the study drug

-- A third group will get a placebo (inactive substance)

- Visit our clinic at the Duke Eye Center up to 13 times.

- Keep in touch with the study team for about 19 months

At various visits, you will have blood draws, answer some questionnaires, and have eye exams and vision tests.

Study Details

Full Title
A randomized, participant and investigator masked, placebo-controlled, multicenter, proof-of-concept study to assess the safety and efficacy of LNP023 (iptacopan) in patients with early and intermediate age-related macular degeneration
Principal Investigator
Protocol Number
IRB: PRO00113751
NCT: NCT05230537
Phase II
Enrollment Status
Open for Enrollment